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Abstract
Background: A persistent goal of oncologic histochemistry is to microscopically identify neoplasia tinctorially.
Consequently, the newly developed CellDetect® staining technology, that appears to exhibit this property, warrants
clinical evaluation. The objective of this study was to compare the diagnostic results using CellDetect® to the
outcomes of standard microscopic examination based on hematoxylin and eosin (H&E) staining for the recognition
of different squamous epithelial phenotypes of the uterine cervix.
Methods: Pairs of adjacent sections were made from 60 cervical biopsy cases that were diagnosed originally as
either normal or neoplastic (CIN, SCC). One section of the pair was stained for H&E; the second section, with
CellDetect®. Based on the examination of these pairs by two experienced pathologists, we investigated the
following issues:(1) diagnostic agreement between the pathologists on each pair; (2) agreement between H&E and
CellDetect® for each pair (3) tinctorial characteristics in micro-regions (n = 130) evaluated as either normal, reactive
or neoplastic.
Results: Qualitatively, CellDetect®-stained preparations displayed cyto-morphological detail comparable to H&E
images. Tinctorially, non-neoplastic cells appeared green/blue when stained withCellDetect®, contrasting with
cytologically neoplastic foci, where cells of every grade were red/magenta in color. Due to these tinctorial
characteristics, even small foci of neoplasia could be readily distinguished that were inconspicuous on H&E at low
magnification. In some instances, this prompted re-examination of the H&E and revision of the diagnosis.
Quantitatively, we found that despite diagnostic variation between pathologists, in about 3% of the cases, each
pathologist made the same diagnosis regardless of whether CellDetect® or H&E was used, i.e. there was 100% self-
agreement for each pathologist between stains. Particularly noteworthy was the finding of a 0% false negative rate,
coupled with a 10-15% false positive rate. Regarding specificity, the performance in reactive squamous processes
was similar to that observed for morphologically normal squamous epithelium.
Conclusions: In this first order assessment of clinical applicability, CellDetect® staining technology was at least
comparable to results using H&E, and perhaps surperior. CellDetect® provided a uniquely useful tinctorial clue for
the detection of neoplasia, which exhibited an impressive 0% false negative rate. A more extensive, blinded study
is needed to confirm these promising findings.
Background
Although cervical cancer is still one of the major
sources of mortality in women, advances have been
made in combating this disease by early detection and
diagnosis [1]. Cytological screening programs that triage
suspicious epithelial changes for subsequent definitive
biopsy have had a significant impact on achieving
improved therapeutic outcomes. Nonetheless, an assess-
ment of cell or tissue morphology alone may be inade-
quate to detect early indications of neoplasia in some
cases. Due to this limitation of a solely histological
* Correspondence: pavel@bio-light.co.il
1Zetiq Technologies Ltd., Ramat Gan, Israel
Full list of author information is available at the end of the article
Idelevich et al. Diagnostic Pathology 2010, 5:70
http://www.diagnosticpathology.org/content/5/1/70
© 2010 Idelevich et al; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative
Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
reproduction in any medium, provided the original work is properly cited.approach, a range of histochemical, immunocytochem-
ical, and molecular biological approaches have been
used as adjuncts to standard microscopy [2,3]. The latter
methods add information on the unique cell biology
believed to distinguish a neoplastic phenotype [2,4].
However, these adjuncts are not generally informative
on all, or even most, neoplastic conditions. We thus
remain challenged to find a universal light microscopic
diagnostic tool for neoplasia, particularly for recognition
of in situ, pre-malignant states that represent the most
urgent goal of early detection programs.
Recently, Zetiq Technologies Ltd. introduced a new
morpho-histochemical stain for neoplasia, named Cell-
Detect®. This staining technology has been shown to
consistently differentiate cancer from normal tissues and
reactive states in histological and cytological prepara-
tions, as well as cultured cell lines [5,6]. In such stained
preparations, the cytoplasm of normal cells is green-
blue, whereas the cytoplasm of neoplastic elements is
distinctively pink-red or magenta. These differences can
be objectively demonstrated using optical instruments
that discriminate wavelength [5]. Importantly, the mor-
phological characteristics of cells stained with CellDe-
tect® are preserved, allowing the application of standard,
microscopic diagnostic criteria as well. This background
suggested that CellDetect® might serve as a useful
adjunct in clinical applications, since it offers the mor-
phological resolution capabilities of hematoxylin and
eosin (H&E) staining, while providing an additional his-
tochemical dimension for the diagnosis of neoplasia.
Consequently, we undertook this first-order, non-blinded
evaluation of CellDetect®’s performance in assessing cervi-
cal epithelial neoplasia. Towards this end, the CellDetect®
stain was applied to a series of clinical samples represent-
ing different phenotypic states of the cervical squamous
epithelium, from normal to invasive SCC. The diagnosis
made on each CellDetect®-stained section was compared to
the results on an adjacent section stained with standard
H&E. In order to avoid confounding errors due to intra-
observer variability, each pair of slides from all cases was
independently assessed by two pathologists. We found that
the diagnostic results using CellDetect® were completely
comparable to H&E. In one regard CellDetect® staining
was superior because the tinctorial characteristics preferen-
tially facilitated judging the grade of intra-epithelial neopla-
sia microscopically, even at low magnification.
Methods
This was a single-center, non-blinded study using 60
archival cervical biopsy cases with the following diag-
n o s e s :n o r m a l ,2 2c a s e s ;C I N - 2 / 3 ,1 8c a s e s ;s q u a m o u s
cell carcinoma, 20 cases. To assess the staining in mor-
phologically reactive processes, 12 micro-regions (see
below), in these cases, were specifically examined.
All cases were diagnostically re-evaluated using two
new adjacent sections that were cut from a single paraf-
fin block representative of each case. One of these two
sections was stained by the standard H&E procedure,
and the other by the CellDetect® method. All of these
pairs of stained slides were reviewed by two patholo-
gists, independently; their diagnostic conclusions for
each case were compared in regard to: (1) the two stains
as a function of diagnosis and (2) inter-observer agree-
ment for diagnosis in each case.
Staining Protocols
Hematoxylin/Eosin Staining Protocol
Paraffin-embedded tissue samples were sectioned at 4
microns, and mounted on standard microscopic slides.
Deparaffinization was accomplished as follows: immersions
in xylene, twice (3 min each); 100% ethanol, twice (3 min
each); immersion in 95% ethanol, twice (3 min each); dis-
tilled water (3 min). These sections were stained with
hematoxylin, Dye-1, (1 min), washed in tap water until the
water was clear. Sections were stained in eosin, Dye-C, (1-2
min) and washed in tap water, as above. For cover-slipping,
the sections were dehydrated in an ascending series of
ethanol concentrations (50%, 70%, 80%, 95% × 2, 100% ×
2), cleared in xylene (3 - 4 times), and then mounted in
Permount, or an equivalent commercial product.
CellDetect® Staining Protocol
The staining was performed according to the manufac-
turer’s instructions. Although the details of the protocol
and the formulation of the stains are currently proprie-
tary information, the kits contain three ingredients: (1)
an acidophilic red stain, (2) a basophilic green stain, and
(3) a proprietary plant extract necessary for the specific
reaction. The six-step staining protocol was completed
in approximately 30 min.
Slide Evaluation
This was made in two stages.
(1) Comparison of observer performance: Each of the
two experienced pathologists examined each case
with both stains, and made two observations. First,
an overall diagnosis on a case was made. Second,
they recorded whether their own diagnostic impres-
sion on the H&E was in agreement with their
impression based on the CellDetect®-stained slide.
(2) Comparison of individual micro-regions: Morpho-
logical versus tinctorial performance of CellDetect®
relative to H&E, was assessed in multiple, small
regions within each of the 60 biopsies that exhibited
a uniform histological phenotype. These are referred
to as: micro-regions. Since the regional variation
along the squamous epithelium in each case ranged
from normal, CIN or SCC, multiple morphologically
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total number of regions was 130. For each region, a
single pathologist first assessed the morphology
using H&E. Then independently, the same region
was examined in the adjacent section stained with
CellDetect®. Thus two morphological diagnoses were
made on each region, which were compared to the
tinctorial characteristics in CellDetect® of each site.
Results
Qualitative features of CellDetect® staining
Normal cervical squamous epithelium and reactive pro-
cesses of squamous epithelium (see below) stain green/
blue (Figure 1). In contrast, morphologically recogniz-
able neoplastic cells in CellDetect®-stained preparations
always exhibited red/magenta tinged cytoplasm (Figure
2 A ,C ,E ) .T h u s ,i tw a sp o s s i b l et or e c o g n i z en e o p l a s i a ,
even at low magnification, based exclusively on tinctorial
status of the epithelium (Figure 2A, C). Similarly, stain-
ing with CellDetect® highlighted the patchy distribution
of CIN along the epithelium, a feature we exploited for
another aspect of the analysis, considered below. The
tinctorial aspects of the histology also clearly demar-
cated the laminar patterning that is so characteristic of
intra-epithelial neoplasia (Fig 2A). Importantly, such
color-based impressions were readily confirmed at
higher magnification using the same preparation. This
could be accomplished because the CellDetect® stain
preserved critical diagnostic cytological features of neo-
plasia evident in the red-stained cells (Figure 2E).
Quantitative diagnostic performance of CellDetect®
Three aspects of diagnostic performance were assessed:
(1) diagnostic agreement between the pathologists on
each case; (2) the agreement between H&E and CellDe-
tect® for each case, for each pathologist. (3) Micro-regio-
nal evaluations directly comparing morphological
performance (H&E, CellDetect®) with tinctorial charac-
teristics of the same cell populations.
Inter-observer variation for case diagnosis
The final diagnosis rendered on each case by each
pathologist, using both stains together, was different in
2 cases (~3%) cases (Table 1). These discrepancies were
not related to stain used, as documented in the next
section.
Within-observer results between stains
In contrast to the foregoing, each pathologist was
entirely consistent across stains, so that no discrepancy
between H&E and CellDetect® was noted in any case
(Table 1), i.e. each pathologist demonstrated a 100%
inter-stain concordance. These data served as a valida-
tion, enabling a more detailed assessment of the correla-
tions between morphological and tinctorial diagnosis, as
explained in the following sections. Despite this final
outcome, CellDetect® highlighted inconspicuous neopla-
sia in three cases that had initially been overlooked, thus
prompting a re-examination of the H&E and revision of
the diagnosis according to the CellDetect® findings.
Morphology vs. tinctorial characteristics in neoplastic
micro-regions
To more critically compare the performance of CellDe-
tect and H&E, the inherent variation of epithelial pheno-
type often seen in cervical biopsies samples was utilized.
A series of 130 microscopic regions with homogeneous
phenotype, culled from the 60 cases, was examined by a
single pathologist. The pathologist first diagnosed the
f o c u sa se i t h e rn o r m a l ,C I No rS C Cb a s e do nH & E .
Subsequently, the same area was identified morphologi-
cally in the CellDetect® slide, and the tinctorially features
Figure 1 CellDetect® and H&E staining of normal cervical epithelium. Using CellDetect® normal epithelial cells stain green/blue.
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Page 3 of 7Figure 2 CellDetect® (A, C, E)and H&E (B, D, F) staining of neoplastic cervical epithelium. CellDetect® stained neoplastic cells red/magenta,
at every grade. (A) CellDetect® staining of low-intermediate grade CIN. Note that the red staining neoplasia was conspicuously laminar, a feature
facilitating grading even at low magnification. (B) H&E-stained section adjacent to A. (C) CellDetect® staining of high grade CIN. (D) H&E-stained
section adjacent to C. (E) CellDetect® staining of high grade CIN seen at higher magnification than C, to illustrate details of cell morphology.
(F) H&E-stained section adjacent to E.
Idelevich et al. Diagnostic Pathology 2010, 5:70
http://www.diagnosticpathology.org/content/5/1/70
Page 4 of 7were recorded. In all cases of CIN or SCC, cells stained
pink/red, so that the false negative rate was 0%. In con-
trast, loci considered morphologically normal in both
H&E and CellDetect®, stained green/blue in approxi-
mately 90% of cases, i.e. a 10% false positive rate was
observed. Table 2 shows the breakdown of the morpho-
logical status of each micro-region and the accompany-
ing histochemical results. For each micro-region,
staining color was recorded for morphologically normal
and atypical cells. By definition, normal cells were not
found in CIN3 or SCC micro-regions, and atypical cells
were not noted in morphologically normal micro-
regions.
It is important to note, that although Table 2 lists
micro-regions of CIN1, these were incidentally present
in cases actually diagnosed as CIN2/3. CIN1 was recog-
nized based on accepted cytological criteria including
nuclear atypia and koilocytosis. Since CIN1 is character-
ized by atypical squamous cells confined to the lower
one third of the epithelium, the red staining from Cell-
Detect® was limited to the same extent.
Morphology vs. Tinctorial characteristics in reactive
micro-regions To examine the specificity of the histo-
chemical staining reaction to neoplasia, micro-regions
were chosen with morphological characteristics on H&E
of either inflammation or squamous metaplasia. Table 3
summarizes these observations, and provides the data
on normal cells (derived from Table 2), for comparison.
It can be seen that the majority of micro-regions with
any of these diagnoses was most likely to be green
stained. The small percentage of red-stained cells
among cells exhibiting squamous metaplasia is similar
to their incidence in morphologically normal squamous
epithelium.
Discussion
This work represents the results of a first order clinical
assessment of the new dual-function CellDetect®
method. This technological approach claims to tincto-
rially discriminate neoplastic cells while preserving mor-
phology [5]. Using these morphological capabilities, in
conjunction with H&E, cytologically neoplastic cells uni-
formly exhibited a neoplastic histochemical phenotype
with red/pink cytoplasm, i.e. providing a zero false nega-
tive rate.
In contrast, some false positive staining occurs. We
found that 10-15% of morphologically normal squamous
cell foci had cells that stained red/pink, instead of the
expected green/blue. On one hand, this raises the excit-
ing possibility that the CellDetect® method is detecting
pre-neoplastic changes, heralded at this early stage by
some, yet to be defined, metabolic alteration (see
below). On the other hand, it is still possible that an
artifactual, red staining reaction may occur in some nor-
mal cells. In any event, the low level of this phenom-
enon should not affect the application of CellDetect® to
routine diagnostic pathology because it will merely
prompt a re-examination of the morphology in such
false positive instances.
Another significant implication of this phenomenon is
that the same frequency of red-staining micro-regions
was seen in metaplastic and inflammatory squamous
settings. Although relatively few of such cases were
available, the congruence of the findings with the larger
sample of normal loci supports the likelihood that these
conditions will usually stain differentially as normal tis-
sue, suggesting a high level of specificity of the technol-
ogy for neoplasia. Naturally, all of these novel findings
need to be substantiated in a larger, blinded investiga-
tion, which will also include the evaluation of additional
benign conditions such as atrophy and immature squa-
mous metaplasia.
From a qualitative perspective, it is worth underscor-
ing that CellDetect®, proved particularly useful because
the expression of cervical intra-epithelial neoplasia
(CIN) is often spotty, and all foci may not be uniform in
Table 1 Comparison of Pathologists’ assessment using
H&E and CellDetect®
Pathol #1 Pathol #2
Diagnosis H&E CD H&E CD
Normal 21/60* 21/60* 22/60 22/60
CIN 22/60 22/60 22/60 22/60
SCC 17/60 17/60 16/60 16/60
Table 2 Relation of neoplastic morphology to
histochemical results
Dx n Normal Atypical
Green Red Green Red
Normal 47 89% 11% - -
CIN 1* 6 100% 0% 0% 100%
CIN 2 17 88% 12% 0% 100%
CIN 3 23 - - 0% 100%
SCC 37 - - 0% 100%
Total 130
n, number of micro-regions with diagnosis
* CIN1 fields were found in cases diagnosed as CIN2/3
Table 3 Relation of reactive morphology to histochemical
results
Dx n Green Red
Normal 47 89% 11%
Inflammation 5 100% 0%
Metaplasia 7 86% 14%
Total 59
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looked by our two experienced pathologists using the
standard hematoxylin-eosin stained preparations. Cell-
Detect® staining detected neoplasia in these cases. This
prompted re-examination of the H&E and revision of
the diagnosis, thus confirming the heightened detection
sensitivity of the CellDetect® technology. We suspect
that the basis for this superior sensitivity is entirely
visual. The process of CIN is expressed as a laminar cel-
lular change in the epithelium. CellDetect® staining
highlights these changes by forming an intra-epithelial
tangential reddish band. The latter is easily seen even at
low magnification.
The finding of a ~3% variation in case diagnosis,
between the two experienced pathologists, is attributed
to well known factors. These include differences in diag-
nostic criteria for a given grade of neoplasia, or thresh-
old for the diagnosis of neoplasia over normal [7-11].
What is critical to note here is that these differences of
opinion were not influenced by the stain used; H&E and
CellDetect® had the same outcomes for each observer.
In short, the findings indicate the likelihood that Cell-
Detect® preparations will continue to prove as useful as
H&E, and perhaps ultimately, superior because CellDe-
tect® provides both morphological and tinctorial infor-
mation that are diagnostically relevant.
Given the success of the CellDetect® technology, it is
of interest to consider how its performance compares to
other cellular markers for cervical neoplasia. For
instance, one alternative approach is based on immuno-
cytochemical detection of cellular proteins, such as p53,
p16 or HPV viral antigens [12-15 ]. Reports using these
markers show that although the marker may be
expressed in all grades of cervical neoplasia, in some
cases, a particular grade may exhibit no demonstrable
expression. That is to say, cells and epithelia satisfying
morphological criteria for neoplasia fail to demonstrate
the target antigen. In contrast, squamous cells with neo-
plastic cytology always stained appropriately using Cell-
Detect®. An additional complication has been reported
regarding the popular p16 (INK4a) in that this marker
protein may be demonstrable even in cytologically nor-
mal cells [14]. A similar occurrence was found in Cell-
Detect® preparations, but its low incidence should not
impact on routine diagnostics, as discussed earlier.
Due to the dramatic, bi-polar histochemical cytoplas-
mic reaction produced by CellDetect® - red or green - the
question of possible mechanism arises. These observa-
tions prompt the speculation that the staining
phenomenon reflects fundamental shifts in cell structure
and function that underlie the transformation from nor-
mal/reactive states to neoplasia. For instance, most
malignancies characteristically exhibit alternations in
metabolic state [16-18], level of differentiation and rates
of proliferation [19]. Our previous work suggested a rela-
tionship between staining outcome and differentiation. In
that study [5], forced differentiation of malignant cell
lines uniformly converted the red/magenta cytoplasmic
staining to green, as we would anticipate. On the other
hand, proliferation of phenotypically benign cells does
not alter staining. The latter is exemplified by the prolif-
erative basal cell layer, which always exhibits a non-neo-
plastic histochemical phenotype, viz. green cytoplasm.
Although these observations are provocative, a more
direct examination of these issues will be required before
any mechanistic option can be accepted.
Conclusions
In conclusion, the findings in this non-blinded study
substantially support the claim that CellDetect® can tinc-
torially discriminate neoplastic cells while preserving
morphology [5], at least for cervical neoplasia. Despite
interpretative limitations imposed by a non-blinded
experimental design, the outcomes using different stra-
tegies for comparison of morphology and tinctorial qua-
lities, were entirely consistent throughout the study
Clearly, these initial observations are promising, but
they need to be cautiously assessed, and bolstered by a
more extensive, prospective evaluation.
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